[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ferry JA: Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist; 2006 Apr;11(4):375-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
  • Burkitt's lymphoma is a highly aggressive lymphoma identified and described in the last century by Denis Burkitt in Africa, in areas endemic for malaria.
  • Since its initial designation as Burkitt's lymphoma, this type of lymphoma and lymphomas closely resembling it have received a variety of names in different classifications of lymphomas and leukemias: undifferentiated lymphoma, Burkitt's and non-Burkitt's type in the modified Rappaport Classification, malignant lymphoma, small non-cleaved cell, Burkitt's type in the Working Formulation, Burkitt's lymphoma and high-grade B-cell lymphoma, Burkitt-like in the REAL Classification, and acute lymphoblastic leukemia, L3 type in the FAB Classification.
  • With the publication of the WHO Classification of Haematopoietic and Lymphoid Tumors, the nomenclature of this lymphoma has come full circle, and it is once again known simply as Burkitt's lymphoma.
  • In recent years, efforts have focused on improving therapy for this rapidly proliferating neoplasm while minimizing, to the extent possible, treatment-associated toxicity.
  • These efforts have led to the development of high-intensity, short-duration combination chemotherapy that has proven extremely effective for a high proportion of Burkitt's lymphoma patients.
  • The differential diagnosis of Burkitt's lymphoma is broad, and precise diagnosis based on histologic, immunophenotypic, and genetic features remains the critical first step in planning appropriate therapy.
  • [MeSH-major] Burkitt Lymphoma / pathology


2. Levine AM, Seneviratne L, Espina BM, Wohl AR, Tulpule A, Nathwani BN, Gill PS: Evolving characteristics of AIDS-related lymphoma. Blood; 2000 Dec 15;96(13):4084-90
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving characteristics of AIDS-related lymphoma.
  • Over time, the epidemiologic and demographic characteristics of AIDS have changed in the United States, while the use of highly active antiretroviral therapy has changed the natural history of the disease.
  • The goal of the study was to ascertain any changes in the epidemiologic, immunologic, pathologic, or clinical characteristics of AIDS-related lymphoma (ARL) over the course of the AIDS epidemic.
  • Significant changes in the demographic profile of patients with newly diagnosed ARL have occurred, with the later time intervals associated with a higher prevalence in women (P =.25), in Latino/Hispanic individuals (P <.0001), and in those who acquired human immunodeficiency virus (HIV) heterosexually (P =.01).
  • The median CD4(+) lymphocyte count at lymphoma diagnosis has decreased significantly over the years, from 177/dL in the earliest time period (1982-1986), to 53/dL in the last time period from 1995 to 1998 (P =.0006).
  • The pathologic spectrum of disease has also changed, with a decrease in the prevalence of small noncleaved lymphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001).
  • Despite changes in the use of antiretroviral or chemotherapy regimens, the median survival has not significantly changed.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / epidemiology. Central Nervous System Neoplasms / immunology. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / pathology. Comorbidity. Ethnic Groups. Female. HIV Infections / drug therapy. Humans. Life Tables. Los Angeles / epidemiology. Male. Mortality / trends. Retrospective Studies. Risk Factors. Sarcoma, Kaposi / epidemiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11110677.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / SAMHSA HHS / OA / N0A-A1-62540; United States / NCI NIH HHS / CA / R01-CA-55510; United States / NCI NIH HHS / CA / R01-CA50850; etc
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


3. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci; 2009 Jan;100(1):54-61
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern.
  • We examined histological and immunohistochemical changes in 59 patients with B-NHL after rituximab therapy.
  • The patients comprised 32 men and 27 women with a median age of 59 years.
  • Pre-rituximab specimens comprised 34 follicular lymphomas (FL), 11 diffuse large B-cell lymphomas (DLBCL), 10 mantle cell lymphomas, two marginal zone B-cell lymphomas (MZBCL), and two chronic lymphocytic leukemias (CLL).
  • CD20 expression in lymphoma cells was evaluated by immunohistochemistry or flow cytometry.
  • Post-rituximab materials were taken a median of 6 months (4 days to 59 months) after rituximab therapy.
  • Sixteen cases (27%) showed loss of CD20 expression with four histological patterns: pattern 1, no remarkable histological change (FL, 5; DLBCL, 3; and CLL, 2); pattern 2, proliferation of plasmacytoid cells (FL, 2; DLBCL, 1; and MZBCL, 1); pattern 3, transformation to classical Hodgkin's lymphoma (FL, 1); and pattern 4, transformation to anaplastic large cell lymphoma-like undifferentiated lymphoma (FL, 1).
  • Loss of CD20 was unrelated to the interval of biopsies, treatment regimen, clinical response, and frequency of rituximab administration.
  • Loss of CD20 within 1 month of rituximab therapy (3/14, 21%) and regain of CD20 (2/7, 29%) were not frequent.
  • In conclusion, B-NHL showed various histological and immunophenotypic changes after rituximab therapy, including not only CD20 loss but also proliferation of plasmacytoid cells or transformation to special subtypes of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038008.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Yoshii T, Horiguchi A, Shirotake S, Tobe M, Hayakawa M, Sumitomo M, Asano T: [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]. Hinyokika Kiyo; 2010 Nov;56(11):639-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma].
  • We report a rare case in which upper ureteral rupture was the primary symptom of malignant lymphoma.
  • Computed tomography showed urinoma around the left kidney and retrograde pyelography showed a diffuse filling defect in the left ureter and a rupture of the upper portion of that ureter.
  • A urine cytology specimen from the left ureter was class V, suggesting undifferentiated carcinoma or malignant lymphoma.
  • An open laparotomy revealed a nodule on the omentum and diffuse fibrosis around both ureters, and the histopathological diagnosis was diffuse large B-cell lymphoma.
  • The patient' s ureteral stenosis disappeared after she received six cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab) chemotherapy.
  • We should be aware that malignant lymphoma can be the cause of a spontaneous ureteral rupture.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Ureteral Diseases / etiology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Pandit-Taskar N, Batraki M, Divgi CR: Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med; 2004 Aug;45(8):1358-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
  • Bone metastasis occurs as a result of a complex pathophysiologic process between host and tumor cells leading to cellular invasion, migration adhesion, and stimulation of osteoclastic and osteoblastic activity.
  • Several sequelae occur as a result of osseous metastases and resulting bone pain can lead to significant debilitation.
  • Pharmaceutical therapy of bone pain includes nonsteroidal analgesics and opiates.
  • These drugs are associated with side effects, and tolerance to these agents necessitates treatment with other modalities.
  • Bisphosphonates act by inhibiting osteoclast-mediated resorption and have been increasingly used in treatment of painful bone metastasis.
  • While external beam radiation therapy remains the mainstay of pain palliation of solitary lesions, bone-seeking radiopharmaceuticals have entered the therapeutic armamentarium for the treatment of multiple painful osseous lesions. (32)P has been used for >3 decades in the treatment of multiple osseous metastases.
  • The myelosuppression caused by this agent has led to the development of other bone-seeking radiopharmaceuticals, including (89)SrCl, (153)Sm-ethylenediaminetetramethylene phosphonic acid ((153)Sm-EDTMP), (179m)SnCl, and (166)Ho-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonate ((166)Ho-DOTMP). (89)Sr is a bone-seeking radionuclide, whereas (153)Sm-EDTMP is a bone-seeking tetraphosphonate; both have been approved by the Food and Drug Administration for the treatment of painful osseous metastases.
  • While both agents have been shown to have efficacy in the treatment of painful osseous metastases from prostate cancer, they may also have utility in the treatment of painful osseous metastases from breast cancer and perhaps from non-small cell lung cancer.
  • We conclude with recommended guidelines for therapy and follow-up.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Pain / etiology. Pain / radiotherapy. Palliative Care / methods. Patient Care Management / methods. Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15299062.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals
  • [Number-of-references] 70
  •  go-up   go-down


6. Wang XY, Ishida T, Ichihara M, Kiwada H: Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release; 2005 May 5;104(1):91-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, when for the first injection small-size liposomes (60 nm) were used, either charged or PEG-modified, but not neutral, the ABC phenomenon was clearly manifest.
  • Also when for the second dose small-size PEGylated liposomes were used, the ABC phenomenon was observed after induction by a first injection of PL, whereas plasma kinetics and organ uptake of a second dose of negatively charged CL (NCL, 110 nm) or small-sized NCL (SNCL, 60 nm) were not altered.
  • Our observations may have a considerable impact on the clinical application and engineering of liposomal formulations for use in multiple drug therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15866337.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Liposomes; 0 / Phospholipids; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


9. Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL: Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol; 2000 May;18(10):2017-25
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study.
  • PURPOSE: To examine the impact of initial CNS involvement on outcome and patterns of failure in patients with disseminated small noncleaved-cell lymphoma and B-cell leukemia who were treated in four successive Children's Cancer Group trials.
  • All patients received protocol-based systemic and intrathecal chemotherapy.
  • The 3-year event-free survival +/- SE for all patients with CNS+ disease was 45% +/- 7%.
  • Patients with CSF+/Mass had a nominally higher treatment failure rate compared with patients with CNS- after adjusting for marrow status and lactate dehydrogenase (LDH) diagnosis, with a relative failure rate (RFR) of 1.52 (95% confidence interval [CI], 0.88 to 2.6; P =.15).
  • CONCLUSION: We conclude that, with the treatments used during the period covered by these studies, the presence of CSF+/Mass CNS disease at diagnosis was associated with a nominally worse outcome independent of initial bone marrow status and LDH level, but the effect was not statistically significant.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Leukemia, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Infant. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use. Proportional Hazards Models. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811665.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; COMP protocol
  •  go-up   go-down


10. Levine AM: Challenges in the management of Burkitt's lymphoma. Clin Lymphoma; 2002 Dec;3 Suppl 1:S19-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges in the management of Burkitt's lymphoma.
  • Burkitt's lymphoma and small noncleaved Burkitt's-like lymphoma are rare and are highly aggressive forms of non-Hodgkin's lymphoma that are characterized by dysregulation of the c-myc oncogene.
  • Patients with human immunodeficiency virus (HIV) also appear to be at risk for developing Burkitt's lymphomas.
  • Treatment options for Burkitt's lymphoma involve complex chemotherapy regimens that contain as many as 10 cytotoxic agents.
  • Approximately 50%-80% of adult patients with Burkitt's lymphoma or small, noncleaved lymphoma can be cured with these intensive chemotherapy regimens, and in pediatric populations, the cure rate is even higher.
  • However, a number of factors often compromise the outcome of patients with Burkitt's lymphoma.
  • For instance, the high proliferation rate of Burkitt's lymphoma enhances the risk for tumor lysis syndrome, which results from metabolic imbalances, such as hyperuricemia, that occur as large numbers of malignant cells are lysed during cytotoxic chemotherapy.
  • Standard treatment for tumor lysis syndrome includes adjustments in the chemotherapy regimen, vigorous hydration, administration of a uric acid synthesis inhibitor like allopurinol, and alkalinization.
  • The lifetime risk of developing central nervous system disease is 20%-30% for Burkitt's lymphoma.
  • Consequently all chemotherapy regimens with activity in Burkitt's lymphoma utilize some form of central nervous system prophylaxis, such as systemic or intrathecal methotrexate or cytarabine.
  • In the past, patients with HIV who developed Burkitt's lymphoma often received inadequate chemotherapy doses because of their immunosuppression.
  • With the discovery of highly active antiretroviral therapy, the ability to treat and control Burkitt's lymphoma in patients with HIV has improved.
  • [MeSH-major] Burkitt Lymphoma / therapy
  • [MeSH-minor] Adult. Allopurinol / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Enzyme Inhibitors / therapeutic use. Etoposide / therapeutic use. HIV Infections / complications. Humans. Ifosfamide / therapeutic use. Leucovorin / therapeutic use. Methotrexate / therapeutic use. Time Factors. Treatment Outcome. Urate Oxidase / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12521385.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 63CZ7GJN5I / Allopurinol; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase; Q573I9DVLP / Leucovorin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol; M-BACOD protocol
  • [Number-of-references] 31
  •  go-up   go-down


11. Manolopoulos L, Nikolopoulos TP, Yiotakis J, Karapatsas J, Maris A, Ferekidis E: Burkitt's lymphoma in the base of the tongue: differential diagnosis and management. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):226-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in the base of the tongue: differential diagnosis and management.
  • Burkitt's lymphoma is the most common malignancy in African children but can occur sporadically in every country.
  • However, complex chemotherapy regimens can now cure approximately 50-80% of adult patients with Burkitt's lymphoma or small noncleaved lymphoma, and in pediatric populations the cure rate is even higher.
  • Although the African type has a preference to the head and neck region (whereas the sporadic type to the abdomen), involvement of the base of the tongue is extremely rare as only 1 case has ever been reported in the English literature.
  • The present study describes a patient with Burkitt's lymphoma presenting as a single mass in the base of the tongue without any abdominal or other extra-abdominal involvement.
  • The patient was submitted to chemotherapy (intravenous and intrathecal) and skull radiotherapy.
  • Physicians should be aware of the extranodal manifestations of Burkitt's lymphoma and their differential diagnosis in order to achieve early diagnosis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Tongue Neoplasms / diagnosis. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564099.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


12. Yang T, Belverud S, Yeh AY, Bandovic J, Farmer P, Woldenberg RF, Demopoulos A, Schulder M, Li JY: Primary CNS anaplastic diffuse large B-cell lymphoma mimicking undifferentiated metastatic tumors: a case report. J Neurooncol; 2010 Feb;96(3):433-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS anaplastic diffuse large B-cell lymphoma mimicking undifferentiated metastatic tumors: a case report.
  • Primary central nervous system lymphoma (PCNSL) is a rare intracranial tumor, with an annual incidence of six per million population.
  • Anaplastic variant of primary CNS diffuse large B-cell lymphoma is less common; to our knowledge, there is only one other case report in the world literature.
  • The patient underwent craniotomy for tumor biopsy, followed by high-dose methotrexate-based chemotherapy despite a remarkably low performance status.
  • Histologically, this tumor was composed of undifferentiated polymorphic tumor cells, multi-nucleated giant cells, extensive necrosis, and conspicuous mitotic activity, mimicking undifferentiated metastatic tumors.
  • The clinical course, diagnostic workup, pathologic correlates, and treatment outcomes are described.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis


13. Satoh S, Saito T, Akiba J, Kato Y, Suzuki K, Yoshino M, Tajima K, Hayashi T, Kato T: [Burkitt's lymphoma occurring as a primary lymphomatous effusion]. Rinsho Ketsueki; 2000 Apr;41(4):329-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma occurring as a primary lymphomatous effusion].
  • Specimens of ascitic fluid contained numerous cells with a FAB-L3 appearance, and small noncleaved cell lymphoma morphology.
  • Bone marrow aspiration showed no infiltration of malignant cells.
  • These findings suggested that Burkitt's lymphoma had developed in the peritoneal cavity as a primary lymphomatous effusion.
  • Chemotherapy with methotrexate, cyclophosphamide, vincristine, doxorubicin, etoposide, and dexamethasone was effective, and the patient has been free from the disease for 1 year since completion of consolidation treatment with autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Ascitic Fluid / diagnosis. Burkitt Lymphoma / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10846464.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


14. Ishii K, Yamamoto Y, Nomura S: [CD30-negative diffuse large B-cell lymphoma expressing ALK]. Rinsho Ketsueki; 2005 Jul;46(7):501-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD30-negative diffuse large B-cell lymphoma expressing ALK].
  • A 33-years-old man was diagnosed as having undifferentiated carcinoma presenting with right neck lymphadenopathy in December 2000.
  • He obtained complete remission (CR) following chemotherapy, radiation and lymphadenectomy on the right neck.
  • An open-abdominal lymph node biopsy was performed from which a diagnosis of anaplastic large cell lymphoma was made.
  • He underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from his HLA-matched sister while in non-CR in November 2002.
  • Engraftment was achieved on day 14, and at the same time, complete chimerism was confirmed.
  • Acute grade III graft-versus-host disease (GVHD) developed and was controlled with cyclosporine A and prednisolone.
  • The tumor cells were ALK-positive, CD30-negative and JH rearrangement was detected, and were therefore classified as diffuse large B-cell lymphoma with expression of ALK according to the WHO classification, though they differed from this subtype in some points.
  • Although this case was refractory for chemotherapy with a complex karyotype, the graft-versus-lymphoma effect might have contributed to the sustained CR following the PBSCT.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Protein-Tyrosine Kinases
  • [MeSH-minor] Adult. Antigens, CD30. Combined Modality Therapy. Fatal Outcome. Humans. Male. Peripheral Blood Stem Cell Transplantation. Peripheral Vascular Diseases / etiology. Receptor Protein-Tyrosine Kinases. Transplantation, Homologous

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440742.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


15. Martyn DC, Ramirez AP, Beattie MJ, Cortese JF, Patel V, Rush MA, Woerpel KA, Clardy J: Synthesis of spiro-1,2-dioxolanes and their activity against Plasmodium falciparum. Bioorg Med Chem Lett; 2008 Dec 15;18(24):6521-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Artemisinin-derived compounds play an integral role in current malaria chemotherapy.
  • The endoperoxide functionality was generated by the SnCl(4)-mediated annulation of a bis-silylperoxide and an alkene.
  • [MeSH-minor] Amines / chemistry. Amino Acid Motifs. Animals. Antigens, Protozoan / chemistry. Antimalarials / chemical synthesis. Antimalarials / pharmacology. Chemistry, Pharmaceutical. Drug Design. Heme / chemistry. Humans. Malaria / drug therapy. Models, Chemical. Peroxides / chemistry. Plasmodium falciparum

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18993067.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amines; 0 / Antigens, Protozoan; 0 / Antimalarials; 0 / Antiprotozoal Agents; 0 / Dioxolanes; 0 / Peroxides; 42VZT0U6YR / Heme
  •  go-up   go-down


16. Laver JH, Mahmoud H, Pick TE, Hutchison RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2002 Jan;43(1):105-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • PATIENTS AND METHODS: One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve remission.
  • CONCLUSION: The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prednisone / administration & dosage. Prospective Studies. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA05587; United States / NCI NIH HHS / CA / CA11233; United States / NCI NIH HHS / CA / CA15089; United States / NCI NIH HHS / CA / CA20549; United States / NCI NIH HHS / CA / CA25408; United States / NCI NIH HHS / CA / CA28383; United States / NCI NIH HHS / CA / CA28476; United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30696; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA35587; United States / NCI NIH HHS / CA / CA69177; United States / NCI NIH HHS / CA / CA69428
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ACOP protocol 2
  •  go-up   go-down


17. Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ, Pediatric Oncology Group: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2001 Jul;42(3):399-405
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve.
  • In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Child. Continental Population Groups. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Neoplasm Metastasis. Prednisolone / administration & dosage. Prednisone / administration & dosage. Remission Induction. Time Factors. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699405.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; VAP-cyclo protocol; VPD protocol
  •  go-up   go-down


18. Vicentini L, Grossano L, Pruneri G, Roncaglia O: [Primary large B-cell lymphoma of the thyroid. Apropos of 2 cases]. Minerva Chir; 2000 Jul-Aug;55(7-8):545-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary large B-cell lymphoma of the thyroid. Apropos of 2 cases].
  • [Transliterated title] Linfoma primitivo della tiroide a larghe cellule B. A proposito di due casi.
  • Two cases of primary large B-cell non-Hodgkin's lymphoma are described.
  • The differential diagnosis between undifferentiated carcinoma and lymphoma of the thyroid, uncertain with clinical and ultrasound examination, was defined by a fine needle biopsy (FNAB).
  • Histological examination of the surgical specimen confirmed the presence of a large B-cell non-Hodgkin's lymphoma while the immunophenotypical analysis detected the expression of the common leukocytic antigen and B-correlated antigens CD20, CD74, CDW75 and CD79A.
  • In both cases chemotherapy and radiotherapy were carried out.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Needle. Carcinoma / diagnosis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunophenotyping. Iodine Radioisotopes. Middle Aged. Radiotherapy, Adjuvant. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11140111.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  •  go-up   go-down


19. Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS: Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol; 2002 May 1;20(9):2293-301
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.
  • PURPOSE: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma.
  • EFS in 17 patients treated with chemotherapy and radiation was 70.1% +/- 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P =.03).
  • EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2% +/- 5.3%, and in five patients with nonhistology-directed treatment it was 40.0% +/- 21.9% (P <.001).
  • CONCLUSION: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies.
  • Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981000.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Hsu CF, Ko SF, Hsiao CC, Shieh CS, Huang CC, Huang FC: Obstructive jaundice as the presenting manifestation of Burkitt's lymphoma in a 4-year-old boy. J Formos Med Assoc; 2003 Feb;102(2):105-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice as the presenting manifestation of Burkitt's lymphoma in a 4-year-old boy.
  • Obstructive jaundice often occurs as a late manifestation of non-Hodgkin's lymphoma (NHL), but has rarely been reported as a presenting manifestation, especially in children.
  • We report a case of a 4-year-old boy with Burkitt's lymphoma (small non-cleaved cell NHL) who presented with obstructive jaundice, resulting from encasement of the common bile duct by the tumor.
  • Combined chemotherapy was not given because of refusal by his family.
  • He received chemotherapy and the jaundice disappeared within 6 days.
  • Follow-up computed tomography 1 year later revealed total resolution of the tumor.
  • Second, relief of obstructive jaundice can be effectively accomplished by chemotherapy alone.
  • Third, chemotherapy should be given once NHL is diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12709739.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


21. Xanthopoulou MN, Hadjikakou SK, Hadjiliadis N, Schürmann M, Jurkschat K, Michaelides A, Skoulika S, Bakas T, Binolis J, Karkabounas S, Charalabopoulos K: Synthesis, structural characterization and in vitro cytotoxicity of organotin(IV) derivatives of heterocyclic thioamides, 2-mercaptobenzothiazole, 5-chloro-2-mercaptobenzothiazole, 3-methyl-2-mercaptobenzothiazole and 2-mercaptonicotinic acid. J Inorg Biochem; 2003 Aug 1;96(2-3):425-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five new organotin(IV) molecules with the heterocyclic thioamides; 2-mercaptobenzothiazole (Hmbzt), 5-chloro-2-mercaptobenzothiazole (Hcmbzt), 3-methyl-2-mercaptobenzothiazole (mmbzt) and 2-mercaptonicotinic acid (H(2)mna) of formulae [(n-C(4)H(9))(2)Sn(mbzt)(2)] (1), [(C(6)H(5))(2)Sn(mbzt)(2)] (2), [(CH(3))(2)Sn(cmbzt)(2)].1.7(H(2)O)] (3), [(n-C(4)H(9))(2)SnCl(2)(mmbzt)(2).(CH(2)Cl(2))] (4) and [[(C(6)H(5))(3)Sn](2)(mna).
  • [(CH(3))(2)CO]] (5) have been synthesized and characterized by elemental analysis, 1H-, 13C-NMR, FT-IR and Mössbauer spectroscopic techniques.
  • Crystal structures of molecules 1, 3 and 5 have been determined by X-ray diffraction at 173(1) K (1 and 5) and 293(2) K (3).
  • Compounds 1, 3 and 5 were tested for in vitro cytotoxicity against the cancer cell line of sarcoma cells (mesenchymal tissue) from the Wistar rat, polycyclic aromatic hydrocarbons (benzo[a]pyrene) carcinogenesis.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Organotin Compounds / chemical synthesis. Sarcoma / drug therapy
  • [MeSH-minor] Animals. Benzo(a)pyrene. Cell Survival / drug effects. Crystallography, X-Ray. Molecular Structure. Nicotinic Acids / chemistry. Nicotinic Acids / pharmacology. Rats. Rats, Wistar. Structure-Activity Relationship. Sulfhydryl Compounds / chemistry. Sulfhydryl Compounds / pharmacology. Thiazoles / chemistry. Thiazoles / pharmacology. Thioamides / chemistry. Thioamides / pharmacology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12888279.001).
  • [ISSN] 0162-0134
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nicotinic Acids; 0 / Organotin Compounds; 0 / Sulfhydryl Compounds; 0 / Thiazoles; 0 / Thioamides; 3417WMA06D / Benzo(a)pyrene; EU7D859ABZ / 2-mercaptonicotinic acid
  •  go-up   go-down


22. Koch B, Basu Baul TS, Chatterjee A: p53-dependent antiproliferative and antitumor effect of novel alkyl series of diorganotin(IV) compounds. Invest New Drugs; 2009 Aug;27(4):319-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was carried out to investigate the comparative anti-proliferative and anti-tumor effect of Me(2)SnCl(2.
  • )L(1) (OTC-1), Et(2)SnCl(2.
  • )L(2) (OTC-2) and (n)Bu(2)SnCl.
  • L(2) (OTC-3) in combination with X-rays (1.5 Gy).
  • METHOD: The cytotoxicity of these diorganotin(IV) compounds was studied in human peripheral lymphocytes and the antitumor activity was assessed in Dalton's lymphoma cells.
  • The involvement of proteins that regulate cell cycle and apoptosis was investigated to elucidate the mechanism of their action.
  • CONCLUSION: It could be possible that after treatment with either OTC-3 alone or in combination with X-rays the Dalton's lymphoma cells may die apoptotically after inducing initial delay in cell cycle and thereby survivality of mouse bearing Dalton's Lymphoma cells was increased significantly.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphoma / drug therapy. Organotin Compounds / pharmacology. Tumor Suppressor Protein p53 / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation / drug effects. Humans. Lymphocytes / drug effects. Lymphocytes / metabolism. Male. Mice. X-Rays

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Toxicol. 2008 May;28(4):430-8 [17668440.001]
  • [Cites] Chromosoma. 1975 Dec 10;53(3):223-30 [53133.001]
  • [Cites] Semin Radiat Oncol. 1996 Oct;6(4):284-294 [10717186.001]
  • [Cites] Int J Immunopharmacol. 1993 Apr;15(3):287-91 [8505140.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Apr 15;156(2):141-6 [10198279.001]
  • [Cites] In Vivo. 1995 Jan-Feb;9(1):59-63 [7669950.001]
  • [Cites] Int J Radiat Biol. 2003 Dec;79(12):943-54 [14713572.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Hum Exp Toxicol. 1999 Oct;18(10):619-24 [10557013.001]
  • [Cites] Arch Toxicol. 1998 Mar;72 (4):197-202 [9587013.001]
  • [Cites] Acta Oncol. 2003;42(5-6):546-56 [14596512.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Environ Mol Mutagen. 1997;29(1):98-104 [9020313.001]
  • [Cites] Cancer Lett. 1984 Aug;24(1):45-8 [6498798.001]
  • [Cites] J Inorg Biochem. 1996 Nov 15;64(3):181-95 [8893519.001]
  • [Cites] Mutat Res. 2002 Jan 15;513(1-2):49-59 [11719089.001]
  • (PMID = 18802665.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organotin Compounds; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Baul TS, Basu S, de Vos D, Linden A: Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies. Invest New Drugs; 2009 Oct;27(5):419-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies.
  • Potassium 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-4-methyl-pentanoate (L(1)HK) and potassium 2-{[(E)-1-(2-hydroxyphenyl)alkylidene]amino}-4-methyl-pentanoates (L(2)HK-L(3)HK) underwent reactions with Ph(n)SnCl(4-n) (n = 2 and 3) to give the amino acetate functionalized Schiff base organotin(IV) complexes [Ph(3)SnLH](n)(1-3) and [Ph(2)SnL] (4), respectively.
  • When these organotin(IV) complexes were tested against A498, EVSA-T, H226, IGROV, M19 MEL, MCF7 and WIDR human tumor cell lines, the average ID(50) values obtained were 55, 80 and 35 ng/ml for triphenyltin(IV) compounds 1-3, respectively.
  • The most cytotoxic triphenyltin(IV) compound in the present report (3) with an average ID(50) value of around 35 ng/ml is found to be more cytotoxic for all the cell lines studied than doxorubicin, cisplatin, 5-fluorouracil and etoposide.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Organotin Compounds / chemical synthesis. Organotin Compounds / pharmacology. Schiff Bases / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Crystallography, X-Ray. Humans. Magnetic Resonance Spectroscopy. Molecular Structure. Spectrophotometry, Infrared. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 2002 Feb 1;70(11):1337-45 [11883711.001]
  • [Cites] Eur J Cancer. 1991;27(7):897-900 [1834124.001]
  • [Cites] Met Based Drugs. 1998;5(4):189-96 [18475843.001]
  • [Cites] Parasitol Res. 2003 Sep;91(1):5-11 [12851812.001]
  • [Cites] Met Based Drugs. 1994;1(4):305-9 [18476244.001]
  • [Cites] J Inorg Biochem. 2001 Jul;85(4):297-300 [11551387.001]
  • [Cites] J Biochem. 2003 Oct;134(4):521-8 [14607978.001]
  • [Cites] Bioorg Med Chem Lett. 2002 Jan 7;12(1):61-4 [11738573.001]
  • [Cites] Methods Enzymol. 1997;276:307-326 [27799103.001]
  • [Cites] Acta Crystallogr A. 1995 Jan 1;51 ( Pt 1):33-8 [7702794.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Oct;311(1):22-33 [15173313.001]
  • [Cites] J Inorg Biochem. 2003 Aug 1;96(2-3):425-34 [12888279.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):285-96 [15803155.001]
  • [Cites] J Inorg Biochem. 2005 Jun;99(6):1294-305 [15917083.001]
  • [Cites] Bioinorg Chem Appl. 2004;:43-54 [18365068.001]
  • [Cites] Met Based Drugs. 1998;5(2):83-90 [18475827.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):47S-59S [12235225.001]
  • (PMID = 18941713.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organotin Compounds; 0 / Schiff Bases
  •  go-up   go-down


24. Mikhailova LR, Baltina LA Jr, Baltina LA, Kondratenko RM, Nepogodiev SA, Field RA, Kunert O, Yin MCh: [A simple method of synthesis of triterpene glycosides similar to glycyrrhizic acid and their hepatoprotective activity in vitro]. Bioorg Khim; 2009 Sep-Oct;35(5):686-95
Hazardous Substances Data Bank. GLYCYRRHIZIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A simplified method of synthesis of triterpene l,2-trans-glycosides was developed using the glycosylation of glycyrrhetic acid (GLA) and 18,19-dehydro-GLA by beta-pyranose peracetates in the presence of SnCl(4) and molecular sieves 4 A.
  • The synthesized glycosides exhibited hepatoprotective activity toward the human hepatoma HepG2 cell line on the model of alcohol hepatitis and decreased the level of TNF-alpha protein.
  • [MeSH-major] Glycosides / chemical synthesis. Glycosides / pharmacology. Glycyrrhizic Acid. Hepatitis, Alcoholic / drug therapy. Hepatocytes / metabolism. Triterpenes / chemical synthesis. Triterpenes / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Humans. Models, Biological. Tumor Necrosis Factor-alpha / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915648.001).
  • [ISSN] 0132-3423
  • [Journal-full-title] Bioorganicheskaia khimiia
  • [ISO-abbreviation] Bioorg. Khim.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Glycosides; 0 / Triterpenes; 0 / Tumor Necrosis Factor-alpha; 6FO62043WK / Glycyrrhizic Acid
  •  go-up   go-down






Advertisement